Please assess the completion status of the following clinical trial:

Trial Title: Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria :~* Signed patient informed consent;~* Type 2 diabetes mellitus;~* Treated with at least 1 oral antidiabetic drug (OAD) for at least 6 months;~* Hemoglobin A1c (HbA1c) \>7.0 % and ≤11% within 3 months of study baseline;~* Physicians' decision in accordance with the current local guidelines to add basal insulin glargine U300 to an existing OAD regimen~Exclusion criteria:~* Diabetes mellitus other than type 2;~* Contraindication to insulin glargine U300 according to local product labelling;~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (U300) (Type: None): Insulin glargine (U300) dosage and dosing time as per local product labeling

Based on this trial design, predict the completion outcome and termination type (if applicable).